University healthtech spin-outs sit at one of the most exciting points in the innovation ecosystem. They are often built on world-class research, deep technical expertise and are born out of a genuine desire to improve patient care and outcomes for individuals. However, the journey from academic discovery to deployed healthcare product is definitely not a straight line or necessarily an easy path to navigate. It involves a significant shift from proving not only that a digital solution can work to proving that it can be trusted, regulated, secure, integrated, adopted and paid for.
The CPI’s MARRS report, Turning Innovation into Impact, found that UK MedTech and diagnostics spin-outs face persistent barriers around regulation, NHS adoption, funding, talent and infrastructure. It also highlights a recurring problem: promising technologies often stall before they reach patients because early teams lack the resources, commercial experience or regulatory guidance needed to move beyond the research environment.
For university founders, the findings of the report shouldn’t be considered as discouraging but rather, providing clarification on areas that may need additional focus. The spin-outs that progress and secure funding, are not always the ones with the most impressive science or innovation. Typically, they are the ones that can clearly demonstrate that they can translate scientific promise into a credible deployment plan.
From Technical Proof to Deployable Product
Many university spin-outs begin with a strong technical asset: an algorithm, platform, diagnostic method, device, software tool or data-driven model. But in healthcare, technical performance is only one part of readiness.
A deployable healthtech product needs a defined user, intended use, workflow, hosting model, safety case, evidence plan and commercial pathway. It needs to be clear whether the product will support clinical decision-making, automate part of a workflow, monitor patients, handle sensitive data, integrate into NHS systems or generate outputs that influence care.
These questions are more than just operational details, they shape regulatory classification, evidence requirements, procurement routes, cybersecurity expectations and ultimately investor confidence.
The UK government’s MedTech strategy update describes the innovation pathway in four broad stages: entry point, approvals, funding and commercial, and adoption. This is a useful framework for founders: in addition to invention, healthcare innovation also requires a laser sharp focus on safe, effective use.
Regulation should start earlier than you think
One of the clearest messages from the MARRS report is that regulation is a major barrier for early-stage MedTech and diagnostics ventures. TTOs interviewed for the report described regulatory compliance as costly, complex and difficult to access without specialist support. The report also notes that without early regulatory guidance, promising technologies can stall before they are ready for investment or healthcare impact.
For spin-outs, the lesson is simple: do not treat regulation and compliance as a late-stage hurdle.
Regulatory assumptions influence product design, claims, data requirements, quality management, timelines, funding needs and even the commercial model. A digital health tool that provides general wellbeing insights is very different from software that informs diagnosis or treatment. An AI model used in research is very different from one used in a clinical workflow. A diagnostic assay, connected device or remote monitoring platform will each bring different obligations.
It’s worth stressing that founders do not need every answer on day one. But they do need a credible regulatory hypothesis: what the product is, what claims it will make, which pathway may apply, what evidence will be needed, and what risks need to be managed. You can read more about why your intended use case is one of the most important early decisions in health software development in our recent article here.
The NHS is not a single customer
Many healthtech spin-outs understandably see the NHS as the natural target market. But “we will sell to the NHS” is not a go-to-market strategy.
The MARRS report found that while the NHS is often a primary target market for MedTech companies, many SMEs experience it as one of the largest barriers to adoption. The challenge is structural: fragmented procurement, long pilot requirements, unclear decision-making chains and limited clarity on when innovation will be adopted.
NHS procurement is also moving further toward value-based buying, so suppliers need to show outcomes, whole-system cost, sustainability, and not just the lowest price.
For founders, this means mapping the difference between the user, clinical champion, budget holder, procurement lead, commissioner, information governance team and implementation owner. A clinician may love the technology but have no budget. A pilot may generate enthusiasm but not procurement. A Trust may validate the need but lack capacity to implement. It also means focusing n stronger evidence of impact, better cost-of-ownership arguments, and more tailored engagement with trusts and ICSs as decision-making becomes more locally driven.
NHS England’s engagement on a more integrated, rules-based MedTech pathway reflects this broader system challenge: the NHS wants safe, effective and innovative technologies, but adoption needs clearer routes, funding logic and implementation support. Whilst the NHS is at the forefront of many founder’s minds, do not assume that it has to be your first or only market; for some healthtech spin-outs, international markets may offer clearer regulatory routes, faster commercial adoption, stronger investor appetite, or better-aligned reimbursement pathways.
Hosting, data and integration are commercial issues
For digital health, AI, diagnostics platforms and connected technologies, deployment readiness increasingly depends on technical infrastructure. Where is the product hosted? What data does it process? Does it handle patient-identifiable or special category data? Does it need to integrate with EPR, PAS, LIMS, imaging, wearable, laboratory or third-party systems? Does it require APIs, FHIR, HL7, DICOM, SNOMED CT or other interoperability standards?
These questions are not just for the technical team. They affect adoption, procurement, implementation cost, information governance, cybersecurity and scalability.
NHS Supply Chain’s Medical Technology Innovation Dynamic Purchasing System, for example, highlights requirements around cyber security certification, quality assurance, EC certification, insurance, social value and supplier readiness. For a spin-out, that is a signal: buyers are not only assessing whether the technology works; they are assessing whether the company can safely and reliably supply it.
Investability comes from de-risking
The Royal Academy of Engineering’s Spotlight on Spinouts 2026 shows the scale of the opportunity. Since 2010, more than 2,000 UK university spin-outs have emerged, with 845 active VC-backed spin-outs in the report’s dataset. The report estimates that spin-outs created since 2010 have generated £49bn in combined enterprise value and 27,000 jobs.
But investment follows evidence. Investors want to see that the team understands the risks ahead and has a credible plan to reduce them. For healthtech spin-outs, those risks usually sit across five areas: technology, regulation, clinical evidence, integration and commercial adoption.
A strong spin-out story therefore does not just say: “Our technology is novel.” It says: “We understand the problem, the user, the workflow, the regulatory route, the evidence burden, the data environment, the integration requirements and the route to adoption.”
The readiness question
Before spinning out, raising investment or approaching NHS stakeholders, founders should ask one fundamental question: can this technology move safely, credibly and commercially from research prototype to real-world deployment?
From our work with university spin-outs, we know that the answer rarely depends on technology alone. It depends on whether the team has understood the hosting model, data environment, integration requirements, regulatory assumptions, evidence burden and route to adoption. University healthtech spin-outs have the potential to improve care, support NHS transformation and create significant economic value. But potential is not enough. The winners will be those that become deployment-ready early: compliant, integrated, evidence-led and commercially credible. Build the product but build the pathway too.
Blüm & Browne Jacobson Spin-out as service
To help universities and founders overcome these barriers, Blüm Health and Browne Jacobson have combined their technical, commercial and legal expertise to deliver Spin-out as a Service, an integrated pathway that supports innovations from initial assessment and company formation through to launch and growth. By bringing together expertise in intellectual property, regulation, governance, secure technology and go-to-market strategy, the service helps create scalable, investor-ready businesses with reduced risk, faster timelines and stronger commercial foundations. If you’d like to find out more, please get in touch for an informal chat.